United Therapeutics (UTHR) Short-term Investments (2009 - 2026)

United Therapeutics has disclosed Short-term Investments across 18 years of filings, most recently posting $859.1 million for Q2 2026.

• In Q2 2026, Short-term Investments fell 40.98% year-over-year to $859.1 million; the TTM figure through Jun 2026 stood at $859.1 million (down 40.98% YoY), while the FY2025 annual figure was $1.4 billion, down 13.16% from the prior year.
• Short-term Investments came in at $859.1 million for Q2 2026 at United Therapeutics, down from $874.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $1.9 billion in Q4 2022 to a low of $859.1 million in Q2 2026.
• Average Short-term Investments over 5 years is $1.5 billion, with a median of $1.5 billion recorded in 2022.
• Year-over-year, Short-term Investments surged 81.24% in 2022 and tumbled 40.98% in 2026.
• Over 5 years, Short-term Investments stood at $1.9 billion in 2022, then dropped by 4.85% to $1.8 billion in 2023, then slipped by 12.12% to $1.6 billion in 2024, then slipped by 13.16% to $1.4 billion in 2025, then plunged by 36.98% to $859.1 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $859.1 million in Q2 2026, $874.0 million in Q1 2026, and $1.4 billion in Q4 2025.